Immune Design
Aug 12, 2015

Immune Design Reports Second Quarter 2015 Financial Results

Company to Hold Conference Call at 1:30 pm Pacific Today

SEATTLE and SOUTH SAN FRANCISCO, Calif., Aug. 12, 2015 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today reported financial results and a corporate update for the second quarter ended June 30, 2015, which included the announcement of three new immuno-oncology clinical collaborations and a cash position of $129.0 million, inclusive of net proceeds from a public offering in April 2015.

Corporate Update and Recent Highlights

Financial Results and Guidance

Second Quarter

Year-to-Date

Updated Financial Guidance

In consideration of the funds raised through Immune Design's follow-on equity offering in April 2015 and investment in the company's clinical development pipeline, revised 2015 financial guidance is as follows:

Conference Call Information

Immune Design will host a conference call and live audio webcast this afternoon at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the second quarter 2015 financial results and provide a corporate update.

The live call may be accessed by dialing 844-831-3023 for domestic callers and 920-663-6275 for international callers. A live webcast of the call will be available online from the investor relations section of the company website at http://ir.immunedesign.com/events.cfm and will be archived there for 90 days. A telephone replay of the call will be available for five days by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference code: 1144304.

An archived copy of the webcast will be available on Immune Design's website beginning approximately two hours after the conference call. Immune Design will maintain an archived replay of the webcast on its website for at least 30 days after the conference call.

About Immune Design

Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic T cells, while also enhancing other immune effectors, to fight cancer and other chronic diseases. CMB305 and G100, the two-pronged focus of Immune Design's ongoing immuno-oncology clinical programs, are the product of its two synergistic discovery platforms, ZVexTM and GLAASTM. Immune Design has offices in Seattle and South San Francisco. For more information, visit www.immunedesign.com.

Cautionary Note on Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Immune Design's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the timing of initiation, progress and scope of clinical trials for Immune Design's product candidates, the reporting of clinical data regarding Immune Design's product candidates, and estimates regarding cash and investments balance at the end of 2015 and cash to be used in operations for 2015. Many factors may cause differences between current expectations and actual results including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrolment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of Immune Design's collaborators to support or advance collaborations or product candidates and unexpected or ongoing litigation or other disputes. Other factors that may cause Immune Design's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Immune Design's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Immune Design assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Immune Design
Selected Balance Sheet Data 
(In Thousands)
     
  June 30, 2015 December 31, 2014
  (unaudited)   
Cash and cash equivalents   $ 128,998  $ 75,354
Total assets  131,342  78,383
Total current liabilities  6,203  11,947
Total stockholders' equity  125,078  66,346
         
         
Statements of Operation Data (unaudited)        
(In Thousands Except Share and Per Share Amounts)      
         
  Three Months Ended Six Months Ended
  June 30 June 30
  2015 2014 2015 2014
         
Revenues:        
Licensing revenue  $ --  $ 1,000  $ --  $ 1,000
Product sales  19  64  108  89
Other, net  1,761  --  3,610  --
Total revenues  1,780  1,064  3,718  1,089
Operating expenses:        
Cost of product sales  44  18  123  32
Research and development  8,483  3,883  15,946  7,961
General and administrative  3,778  1,850  7,580  3,296
Total operating expenses  12,305  5,751  23,649  11,289
Loss from operations  (10,525)  (4,687)  (19,931)  (10,200)
Interest and other income  8  --  8  1
Change in fair value of convertible preferred stock warrant liability  --  (1,439)  --  (4,150)
Net loss attributable to common stockholders  $ (10,517)  $ (6,126)  $ (19,923)  $(14,349)
Basic and diluted net loss per share attributable to common stockholders  $ (0.54)  $ (16.57)  $ (1.10)  $ (38.81)
Weighted-average shares used to compute basic and diluted net loss per share attributable to common stockholders  19,356,404  369,750  18,174,611  369,702
 
CONTACT: Media Contact

         Julie Rathbun

         Rathbun Communications

         julie@rathbuncomm.com

         206-769-9219



         Investor Contact

         Shari Annes

         Annes Associates

         sannes@annesassociates.com

         650-888-0902

company logo

Source: Immune Design

News Provided by Acquire Media